Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Size: px
Start display at page:

Download "Proton Pump Inhibitors Drug Class Prior Authorization Protocol"

Transcription

1 Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics Subcommittee. Drugs Requiring Prior Authorization Review: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Nexium (esomeprazole granules), Prevacid SoluTab (lansoprazole disintegrating DR), Prilosec (omeprazole granule), Protonix (pantoprazole granule), Zegerid (omeprazole-sodium bicarbonate capsule, packet powder for suspension) Formulary Alternatives: esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole Policy/Criteria: A. Drugs: Dexilant (dexlansoprazole), Zegerid (omeprazole - sodium bicarbonate), Prevacid SoluTab (lansoprazole) Diagnosis: a. Barrett s esophagus b. Erosive esophagitis c. Gastroduodenal ulcer d. H. pylori infection e. Hypersecretory condition (e.g. Zollinger Ellison syndrome, Retained Gastric Antrum syndrome) f. NSAID associated gastric ulcer g. Symptomatic GERD Specialist: No restriction Criteria: a. ONE of the following: i. Failure or clinically significant adverse effects of each formulary PPI alternative (lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole)

2 ii. For patients with documented difficulty swallowing: Trial and failure of formulary omeprazole and lansoprazole capsules sprinkled on apple sauce or juice as directed. iii. For patients with tube feeding: Nexium granule packet and Protonix granule packet are the preferred PPI products. b. Requested dose and duration must be consistent with FDA package labeled recommendation or DrugDex compendia. Clinical Justifications: American College of Gastroenterology: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease 2013 Management of GERD: An 8-week course of PPIs is the therapy of choice for symptom relief and healing of erosive esophagitis. There is no major difference in efficacy between the different PPIs. Traditional delayed release PPIs should be administered minutes before meal for maximal ph control. Newer PPIs may offer dosing flexibility relative to meal timing. PPI therapy should be initiated at once a day dosing, before the first meal of the day. For patients with partial response to once daily therapy, tailored therapy with adjustment of dose timing and/or twice daily dosing should be considered in patients with night-time symptoms, variable schedules, and/or sleep disturbance. Non-responders to PPI should be referred for evaluation. In patients with partial response to PPI therapy, increasing the dose to twice daily therapy or switching to a different PPI may provide additional symptom relief. Maintenance PPI therapy should be administered for GERD patients who continue to have symptoms after PPI is discontinued and in patients with complications including erosive esophagitis and Barrett s esophagus. For patients who require long-term PPI therapy, it should be administered in the lowest effective dose, including on demand or intermittent therapy. Potential Risks Associated with PPIs: Switching PPIs can be considered in the setting of side effects. Patients with known osteoporosis can remain on PPI therapy. Concern for hip fractures and osteoporosis should not affect the decision to use PPI long-term except in patients with other risk factors for hip fracture. PPI therapy can be a risk factor for Clostridium difficile infection and should be used with care in patients at risk. Short-term PPI usage may increase the risk of community acquired pneumonia. The risk does not appear elevated in long-term users. PPI therapy does not need to be altered in concomitant clopidogrel users as clinical data does not support an increased risk for adverse cardiovascular events.

3 American College of Gastroenterology: Diagnosis and Management of Barrett s Esophagus 2015 Therapy: Chemoprevention: Patients with BE should receive once-daily PPI therapy. Routine use of twice-daily dosing is not recommended, unless necessitated because of poor control of reflux symptoms or esophagitis. o PPI therapy is common in patients with BE, in part because of the high proportion of those patients who also have symptomatic GERD. In these cases, the use of PPIs is substantiated by the need for symptom control, making consideration of chemoprevention secondary. o With respect to optimizing medical therapy, dosages of PPI beyond twice daily have not been demonstrated to have beneficial effect in patients with BE. We recommend once-daily PPI therapy for patients with BE unless GERD symptoms require twice daily for adequate symptom control. Aspirin or nonsteroidal anti-inflammatory drugs should not be routinely prescribed to patients with BE as an antineoplastic strategy. Similarly, other putative chemopreventive agents currently lack sufficient evidence and should not be administered routinely. American College of Gastroenterology: Treatment of Helicobacter Pylori Infection 2017 When to test for H.pylori infection: All patients tested positive for H. pylori infection should be offered treatments. Who should be tested for H. pylori infection: o Patients with active peptic ulcer disease (PUD), a past history of PUD (unless previous cure of H. pylori infection has been documented), low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma, or a history of endoscopic resection of early gastric cancer (EGC) o Patients with dyspepsia who is undergoing upper endoscopy o Patients initiating chronic treatment with a non-steroidal anti-inflammatory drug (NSAID) o Patients with unexplained iron deficiency anemia despite an appropriate evaluation o Adults with idiopathic thrombocytopenic purpura (ITP) Who could be tested for H. pylori infection: o Patients with uninvestigated dyspepsia who are under the age of 60 years and without alarm features o Patients who are taking long-term, low-dose aspirin to reduce the risk of ulcer bleeding Who need not be tested for H. pylori infection: o Patients with typical symptoms of gastroesophageal reflux disease (GERD) who do not have a history of PUD o Routine testing for and treatment of H. pylori in asymptomatic individuals with a family history of gastric cancer or patients with lymphocytic gastritis, hyperplastic gastric polyps, and hyperemesis gravidarum

4 Recommended therapies for H. pylori infection: Previous antibiotic exposure(s) should be taken into consideration when choosing an H. pylori treatment regimen In regions where H. pylori clarithromycin resistance is known to be <15% and in patients with no previous history of macrolide exposure: o Clarithromycin triple therapy consisting of a PPI, clarithromycin, and amoxicillin or metronidazole for 14 days is a recommended treatment. Bismuth quadruple therapy consisting of a PPI, bismuth, tetracycline, and a nitroimidazole for days is a recommended first-line treatment option. o Particularly in patients with previous macrolide exposure or who are allergic to penicillin Concomitant therapy consisting of a PPI, clarithromycin, amoxicillin and a nitroimidazole for days is a recommended first-line treatment option Sequential therapy consisting of a PPI and amoxicillin for 5 7 days followed by a PPI, clarithromycin, and a nitroimidazole for 5 7 days is a suggested first-line treatment option Hybrid therapy consisting of a PPI and amoxicillin for 7 days followed by a PPI, amoxicillin, clarithromycin and a nitroimidazole for 7 days is a suggested first-line treatment option Levofloxacin triple therapy consisting of a PPI, levofloxacin, and amoxicillin for days is a suggested first-line treatment option Fluoroquinolone sequential therapy consisting of a PPI and amoxicillin for 5 7 days followed by a PPI, fluoroquinolone, and nitroimidazole for 5 7 days is a suggested firstline treatment option Post-treatment recommendation: Whenever H. pylori infection is identified and treated, testing to prove eradication should be performed using a urea breath test, fecal antigen test or biopsy-based testing at least 4 weeks after the completion of antibiotic therapy and after PPI therapy has been withheld for 1 2 weeks. Salvage therapy recommendations: Avoid antibiotics that have been previously taken by the patient Bismuth quadruple therapy or levofloxacin salvage regimens are the preferred treatment options if a patient received a first-line treatment containing clarithromycin Clarithromycin or levofloxacin-containing salvage regimens are the preferred treatment options, if a patient received first-line bismuth quadruple therapy. Recommended salvage treatment regimens: o Bismuth quadruple therapy for 14 days. o Levofloxacin triple regimen for 14 days. o Concomitant therapy for days. Suggested salvage treatment regimens: o Rifabutin triple regimen consisting of a PPI, amoxicillin, and rifabutin for 10 days. o High-dose dual therapy consisting of a PPI and amoxicillin for 14 days.

5 Clarithromycin triple therapy should be avoided as a salvage regimen. Most patients with a history of penicillin allergy do not have true penicillin hypersensitivity. After failure of first-line therapy, such patients should be considered for referral for allergy testing since the vast majority can ultimately be safely given amoxicillin-containing salvage regimens Therapy Comparison by Indications: Clinical Indications & Dosages Erosive Esophagitis associated with GERD Dexlansoprazole Treatment: 60mg once daily for 8 weeks Maintenance: 30mg once daily for up to 6 months Esomeprazole Treatment: 20-40mg once daily for 4-8 weeks Maintenance: 20mg once daily Lansoprazole Treatment: 30mg once daily for 8-16 weeks (another 8 weeks for recurrence may be considered) Maintenance: 15 mg once daily for up to 12 months Omeprazole Treatment: 20mg once daily for 4-8 weeks (additional 4-8 weeks may be considered) Maintenance: 20mg once daily Omeprazole-sodium Treatment: 20mg daily for 4-8 weeks (additional 4 weeks may be bicarbonate considered) Maintenance: 20mg once daily Pantoprazole Treatment: 40mg once daily for 8 weeks (additional 8 weeks may be considered) Maintenance: 40mg once daily Rabeprazole Treatment: 20mg once daily for 4-8 weeks Maintenance: 20mg once daily Symptomatic GERD Dexlansoprazole 30mg once daily for 4 weeks Refractory GERD: 30mg twice daily Esomeprazole 20mg once daily for 4 weeks (additional 4 weeks may be considered if healing is not complete) Lansoprazole 15mg once daily for 8 weeks Heartburn: 15mg once daily for 14 days Omeprazole 20mg once daily for 4 weeks Refractory GERD: 20 mg twice daily Omeprazole-sodium 20mg once daily for 4 weeks bicarbonate Heartburn: 20mg once daily for 4 weeks Pantoprazole 20mg once daily for 8 weeks

6 Rabeprazole 20mg once daily for 4 weeks NSAID Associated Gastric Ulcer Esomeprazole Treatment: 20mg once daily for 4-8 weeks ± Prevention: 20mg-40mg once daily for 6 months Lansoprazole Treatment: 30mg once daily for 8 weeks Prevention: 15mg once daily for 12 weeks Omeprazole Treatment: 20mg once daily for 4-8 weeks ± Prevention: 20mg once daily for 6 months ± Pantoprazole Prevention: 20mg once daily ± Pathological Hypersecretory Condition (e.g. Zollinger-Ellison Syndrome) Esomeprazole 40mg twice daily Lansoprazole 60mg once daily (up to 90mg twice daily) Omeprazole 60mg once daily (up to 120mg three times daily) Pantoprazole 40mg twice daily (up to 240mg daily) Rabeprazole 60mg once daily (up to 60mg twice daily) Active and Maintenance Therapy of Gastroduodenal Ulcers Lansoprazole Duodenal ulcer: Treatment: 15mg once daily for 4 weeks Maintenance: 15mg once daily Gastric ulcer: Treatment: 30mg once daily for 8 weeks Omeprazole Duodenal ulcer: 20mg once daily for 4 weeks (additional 4 weeks may be considered) Gastric ulcer: 40mg once daily for 4-8 weeks Omeprazole-sodium Duodenal ulcer: 20mg once daily for 4 weeks (additional 4 weeks may be bicarbonate considered) Gastric ulcer: 40mg once daily for 4-8 weeks Pantoprazole Duodenal ulcer: 40-80mg once daily for 4-8 weeks Gastric ulcer: 40mg once daily for 4 weeks (may extend for additional 2-4 weeks) ± Rabeprazole Duodenal ulcer: 20mg once daily for 4 weeks Gastric ulcer: 20mg once daily for 6 weeks ± H. Pylori Eradication Esomeprazole 40mg once daily as part of triple therapy/load regimen 20-40mg twice daily as part of clarithromycin/ levofloxacin sequential regimen 20mg twice daily as part of bismuth quadruple/ concomitant/ sequential/ hybrid/ levofloxacin triple regimen Lansoprazole 30mg twice daily as part of triple therapy

7 Omeprazole Pantoprazole Rabeprazole ± Off labeled use (dual therapy not recommended due to increasing resistance rates- Micromedex) 30mg twice daily as part of bismuth quadruple/ concomitant/ hybrid/ sequential/ levofloxacin triple regimen 30-60mg twice daily as part of levofloxacin sequential/ clarithromycin triple regimen 60mg once daily as part of LOAD regimen 40mg once daily as part of dual therapy/ LOAD regimen 20mg twice daily as part of triple therapy/ bismuth quadruple/ concomitant/ sequential / hybrid/ levofloxacin triple regimen 20-40mg twice daily as part of clarithromycin triple/ levofloxacin sequential/ quadruple regimen 40mg twice daily as part of bismuth quadruple/ concomitant/ sequential/ hybrid/ levofloxacin triple regimen 40-80mg twice daily as part of clarithromycin triple/ levofloxacin sequential regimen 80mg once daily as part of LOAD regimen 20mg twice daily as part of sequential/ levofloxacin triple regimen/ bismuth quadruple/ concomitant/hybrid regimen 20-40mg twice daily as part of clarithromycin triple regimen. Levofloxacin sequential regimen 40mg once daily as part of LOAD regimen References: 1. Katz, PO, Gerson, LB, et al. Am J Gastroenterol 2013; 108: Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017; 112(2): Shaheen NJ, Walk, GW, et al. Am J Gastroenteroladvance online publication, 3 November 2015; doi: /ajg.2015: Micromedex. Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Accessed September 21, Prevacid [Prescribing Information] Deerfield, IL: Takeda Pharmaceuticals; December Prilosec [Prescribing Information] Wilmington, DE: AstraZeneca; July Aciphex/Aciphex Sprinkle [Prescribing Information] Woodcliff Lake, NJ: Eisai, Inc; April Dexilant [Prescribing Information] Deerfield, IL: Takeda Pharmaceuticals; August Nexium [Prescribing Information] Wilmington, DE: AstraZeneca; July 2016.

8 9. Zegerid [Prescribing Information] San Diego, CA: Santarus; June Change Control Date Change 11/15/2017 Document format updated New 2017 American College of Gastroenterology H. pylori guideline Expanded more on H. pylori regimens in the drug comparison table Added esomeprazole to formulary with quantity limit

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,

More information

Treatment of Helicobacter pylori Infection

Treatment of Helicobacter pylori Infection Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk

More information

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division

More information

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf

More information

Proton Pump Inhibitors. Description

Proton Pump Inhibitors. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors

More information

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.209 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

Proton Pump Inhibitors

Proton Pump Inhibitors Market DC Proton Pump Inhibitors Override(s) Prior Authorization Quantity Limit** Approval Duration Preferred PPI: No Prior Authorization required Preferred PPI quantity override: Lifetime Non-Preferred

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. PROTON PUMP INHIBITORS, NON-PREFERRED FORMS: ACIPHEX (rabeprazole sodium EC) oral tablet ACIPHEX SPRINKLE (rabeprazole sodium DR) oral capsule ESOMEPRAZOLE STRONTIUM (esomeprazole strontium DR) oral capsule

More information

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia

More information

Texas Prior Authorization Program Clinical Criteria. This criteria was recommended for review by an MCO to ensure appropriate and safe utilization.

Texas Prior Authorization Program Clinical Criteria. This criteria was recommended for review by an MCO to ensure appropriate and safe utilization. Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by an MCO to ensure appropriate and safe utilization. Clinical Information Included in this

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description

More information

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers

More information

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment

More information

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35. An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology

More information

Committee Approval Date: October 14, 2014 Next Review Date: October 2015

Committee Approval Date: October 14, 2014 Next Review Date: October 2015 Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next

More information

National Digestive Diseases Information Clearinghouse

National Digestive Diseases Information Clearinghouse Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach

More information

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory

More information

Drug Class Literature Scan: Proton Pump Inhibitors and Histamine-2 Receptor Antagonists

Drug Class Literature Scan: Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease

More information

Prevpac Pylera Omeclamox-Pak

Prevpac Pylera Omeclamox-Pak Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,

More information

High use of maintenance therapy after triple therapy regimes in Ireland

High use of maintenance therapy after triple therapy regimes in Ireland High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity

More information

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this

More information

Treating H. pylori in 2016

Treating H. pylori in 2016 Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes

More information

Management of Dyspepsia

Management of Dyspepsia MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively

More information

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI) Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations

More information

Peptic ulcer disease Disorders of the esophagus

Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth

More information

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority

More information

Peptic Ulcer Disease Update

Peptic Ulcer Disease Update Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following

More information

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty. Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole

More information

TEXAS VENDOR DRUG PROGRAM

TEXAS VENDOR DRUG PROGRAM 1 OF 12 Publication History o Revised March 2015; June 2013; November 2011; September 2011; September 20009; June 2009; December 2005; November 2003; October 2002. o Developed December 2001. Prepared by

More information

Clinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153

Clinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153 Clinical Policy: Reference Number: CP.MP.153 Effective Date: 12/17 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation

More information

ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease

ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease Philip O. Katz MD 1, Lauren B. Gerson MD, MSc 2 and Marcelo F. Vela MD, MSCR 3 1 Division of Gastroenterology, Einstein

More information

AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan

AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan AstraZeneca K.K. Daiichi Sankyo Co., Ltd. AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan Osaka and Tokyo, Japan, April 18,

More information

Rpts. GENERAL General Schedule (Code GE)

Rpts. GENERAL General Schedule (Code GE) Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form

More information

QUICK QUERIES. Topical Questions, Sound Answers

QUICK QUERIES. Topical Questions, Sound Answers QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University

More information

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.

More information

Disclosures. Co-founder and Chief Science Officer, TechLab

Disclosures. Co-founder and Chief Science Officer, TechLab H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the

More information

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011 KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,

More information

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for

More information

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection

More information

Proton Pump Inhibitor De-prescribing Guidance

Proton Pump Inhibitor De-prescribing Guidance Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page

More information

Disclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.

Disclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018. Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton

More information

Policy Evaluation: Proton Pump Inhibitors (PPIs)

Policy Evaluation: Proton Pump Inhibitors (PPIs) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Nexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.

Nexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc. NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR

More information

Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection

Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Isabel Lee, MD Associate Professor of Health Sciences UCSF Department of Family and Community Medicine Disclosures None 2 Session

More information

Epidemiology of Peptic Ulcer Disease

Epidemiology of Peptic Ulcer Disease Epidemiology of Peptic Ulcer Disease Introduction Peptic Ulcer Disease (PUD) is disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées

More information

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release capsule (Manufacturer s standard)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release capsule (Manufacturer s standard) READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr PREVACID lansoprazole delayed-release capsule (Manufacturer s standard) Read this carefully before you start taking

More information

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date

More information

Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada

Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and

More information

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori

More information

Peptic Ulcer Disease and NSAIDs

Peptic Ulcer Disease and NSAIDs Peptic Ulcer Disease and NSAIDs National Digestive Diseases Information Clearinghouse What is a peptic ulcer? A peptic ulcer is a sore on the inner lining of the stomach or duodenum the first part of the

More information

Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin

Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin CASE REPORT Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin Takahisa Furuta 1, Mitsushige Sugimoto 2, Mihoko Yamade

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 5 March 2007 Current Practice Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions

More information

PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW

PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related

More information

Management of dyspepsia and of Helicobacter pylori infection

Management of dyspepsia and of Helicobacter pylori infection Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia

More information

Heartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus.

Heartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus. WHILE almost everyone experiences mild heartburn from time to time and many individuals have some antacids or another medication on hand for its relief, talk to your doctor, if you have heartburn more

More information

Second Asia Pacific Consensus Guidelines for Helicobacter pylori infection

Second Asia Pacific Consensus Guidelines for Helicobacter pylori infection doi:10.1111/j.1440-1746.2009.05982.x SPECIAL ARTICLE jgh_5982 1587..1600 Second Asia Pacific Consensus Guidelines for Helicobacter pylori infection K Ming Fock,* Peter Katelaris, Kentaro Sugano, Tiing

More information

PLANNING COMMITTEE. Seek simplicity, and mistrust it. Alfred North Whitehead

PLANNING COMMITTEE. Seek simplicity, and mistrust it. Alfred North Whitehead PLANNING COMMITTEE 1. Content Experts Clinical experts Desmond Leddin MB FRCPC, Head, Division of Gastroenterology, Dalhousie University Drug evaluation pharmacist Pam McLean-Veysey BScPharm, Drug Evaluation

More information

LONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS. Jihane Naous, M.D.

LONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS. Jihane Naous, M.D. LONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS Jihane Naous, M.D. Objectives Identify the conditions supported by AGA/ACG guidelines necessitating long-term use of daily PPIs, Recognize which

More information

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009 Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,

More information

PREVACID is used in children and adolescents (ages 1 to 17): for up to 12 weeks to treat GERD and erosive esophagitis in children 1 to 11 years old.

PREVACID is used in children and adolescents (ages 1 to 17): for up to 12 weeks to treat GERD and erosive esophagitis in children 1 to 11 years old. MEDICATION GUIDE PREVACID (prev-a-sid) Delayed-Release Capsules and PREVACID SoluTab (prev-a-sid sol-u-tab) Delayed-Release Orally Disintegrating Tablets Read this Medication Guide before you start taking

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Duexis) Reference Number: CP.PMN.120 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

MEDICATION GUIDE Lansoprazole Delayed-Release Capsules, USP

MEDICATION GUIDE Lansoprazole Delayed-Release Capsules, USP MEDICATION GUIDE Lansoprazole Delayed-Release Capsules, USP Read this Medication Guide before you start taking lansoprazole delayed-release capsules and each time you get a refill. There may be new information.

More information

Administration of Proton Pump Inhibitors In Patients Requiring Enteral Nutrition

Administration of Proton Pump Inhibitors In Patients Requiring Enteral Nutrition Administration of Proton Pump Inhibitors In Patients Requiring Enteral Nutrition Terri M. Wensel, PharmD Key words: proton pump inhibitor, enteral, administration INTRODUCTION Role of Proton Pump Inhibitors

More information

Difference between omeprazole and omeprazole delayed release

Difference between omeprazole and omeprazole delayed release Cari untuk: Cari Cari Difference between omeprazole and omeprazole delayed release 7-2-2018 Easy to read patient leaflet for Omeprazole Delayed-Release Capsules. Includes indications, proper use, special

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based

More information

CYP2C19-Proton Pump Inhibitors

CYP2C19-Proton Pump Inhibitors CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the

More information

HELICOBACTER PYLORI UPDATE

HELICOBACTER PYLORI UPDATE HELICOBACTER PYLORI UPDATE PROF. TAWHEED MOWAFY DEAN OF AZAL FACULTY OF MEDICINE INTRODUCTION (H. pylori) is recognised as the most common chronic human bacterial infection,1 affecting up to 50% of the

More information

MEDICATION GUIDE. PREVACID can have other serious side effects. See What are the possible side effects of PREVACID?

MEDICATION GUIDE. PREVACID can have other serious side effects. See What are the possible side effects of PREVACID? Page 33 of 39 MEDICATION GUIDE PREVACID (prev-a-sid) (lansoprazole) Delayed-Release Capsules and PREVACID SoluTab (prev-a-sid sol-u-tab) (lansoprazole) Delayed-Release Orally Disintegrating Tablets Read

More information

Low Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial

Low Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial Global Journal of Health Science; Vol. 7, No. 1; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Low Dose Furazolidone for Eradication of H- pylori Instead of

More information

GERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University

GERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.

More information

All Indiana Medicaid Prescribers and Pharmacy Providers

All Indiana Medicaid Prescribers and Pharmacy Providers P R O V I D E R B U L L E T I N BT200148 NOVEMBER 28, 2001 To: All Indiana Medicaid Prescribers and Pharmacy Providers Subject: Note: The information in this bulletin regarding prior authorization payment

More information

GERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018

GERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018 GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update

More information

MEDICATION GUIDE. Rabeprazole Sodium Delayed-Release Tablets Rx Only

MEDICATION GUIDE. Rabeprazole Sodium Delayed-Release Tablets Rx Only MEDICATION GUIDE Rabeprazole Sodium Delayed-Release Tablets Rx Only Read the Medication Guide that comes with rabeprazole sodium delayed-release tablets before you start taking it and each time you get

More information

II. Angiotensin Receptor Blockers (ARBs) Drug Class Review

II. Angiotensin Receptor Blockers (ARBs) Drug Class Review DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,

More information

You May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Pantoprazole (Pantoloc, Panto IV )

You May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Pantoprazole (Pantoloc, Panto IV ) You May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Esomeprazole (Nexium ) Omeprazole (Losec, Olex ) Pantoprazole (Pantoloc, Panto IV ) Pantoprazole

More information

OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)

OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I) ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE

More information

11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.

11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated. REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric

More information

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,

More information

Drug Class Review on Proton Pump Inhibitors

Drug Class Review on Proton Pump Inhibitors Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May

More information

Proton Pump Inhibitors:

Proton Pump Inhibitors: Proton Pump Inhibitors: How bad could they be? Andrea Flanagan, Pharm.D. Iowa City VA Medical Center PGY-1 Pharmacy Resident Objectives for Pharmacists At the end of this presentation PHARMACISTS should

More information

Original Policy Date

Original Policy Date MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release tablet

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release tablet READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr PREVACID FasTab lansoprazole delayed-release tablet Read this carefully before you start taking PREVACID FasTab and

More information

Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI

Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Jun Heng Lee, M.D. Samsung Medical Center, Sungkyunkwan University

More information

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb

More information

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both

More information

S. Sandberg-Lewis, ND, DHANP

S. Sandberg-Lewis, ND, DHANP Functional Gastroenterology Webinar One 6-28-13 S. Sandberg-Lewis, ND, DHANP Proton pump inhibitors- Effects on: secretion gastric mucosa food allergy bile reflux Barrett metaplasia and dysplasia esophageal

More information

Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases

Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases p1009 DRUGS USED IN ACID-PEPTIC DISEASES 1. classification of drugs 2. agents that reduce intragastric acidity Antacids,H 2 antagonists,proton

More information

Management of dyspepsia in adults in primary care

Management of dyspepsia in adults in primary care Dyspepsia Management of dyspepsia in adults in primary care June 2005. The recommendations on referral for endoscopy in this NICE guideline have been amended in line with the recommendation in the NICE

More information

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018 GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Z Gastroenterol. 1983 Mar;21 Suppl:111-6. [Effect of antacids on intestinal motility]. [Article in German] Wienbeck M, Erckenbrecht J, Strohmeyer G. Abstract

More information

National Digestive Diseases Information Clearinghouse

National Digestive Diseases Information Clearinghouse Gastritis National Digestive Diseases Information Clearinghouse What is gastritis? Gastritis is a condition in which the stomach lining known as the mucosa is inflamed, or swollen. The stomach lining contains

More information

Philadelphia College of Osteopathic Medicine. Shawn P. Mahoney Philadelphia College of Osteopathic Medicine,

Philadelphia College of Osteopathic Medicine. Shawn P. Mahoney Philadelphia College of Osteopathic Medicine, Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Esomeprazole (Nexium) More Effective

More information

235 60th Street, West New York, NJ T: (201) F: (201) Main Street, Hackensack, NJ T: (201)

235 60th Street, West New York, NJ T: (201) F: (201) Main Street, Hackensack, NJ T: (201) 235 60th Street, West New York, NJ 07093 T: (201) 854-4646 F: (201) 854-4647 810 Main Street, Hackensack, NJ 07601 T: (201) 488-0095 Barrett's Esophagus WHAT IS BARRETTT'S ESOPHAGUS? Barrett's esophagus

More information

long term use Nexium Nexium

long term use Nexium Nexium NEXIUM 40 mg Tablets - Summary of Product Characteristics (SPC) by AstraZeneca Pharmaceuticals (Ireland) DAC. Nexium 20mg, 40mg Tablets - Patient Information Leaflet (PIL) by AstraZeneca UK Limited. Information

More information